Company news
Noxopharm Ltd. (ASX:NOX) news
Noxopharm Ltd. news releases on 6ix. Latest, Aug 31, 2026: Novel oligonucleotides data presented at Options Conference
Press releases & updates
Novel oligonucleotides data presented at Options Conference
August 31, 2026
Appendix 4E - Preliminary Financial Report
August 28, 2026
New preclinical data supports immuno-oncology approach
August 25, 2026
Quarterly Activities/Appendix 4C Cash Flow Report
July 21, 2026
SOF-SKN manufacturing begins to ensure clinical trial readi
June 8, 2026
New data confirms cancer-fighting potential
May 25, 2026
Noxopharms Sofra assets to be presented at global conference
May 19, 2026
Noxopharm progresses US regulatory strategy
May 5, 2026
New data shows SOF-SKN active ingredient efficacy
April 30, 2026
Innovative collaboration further expands Sofra platform
April 26, 2026
March 2026 Quarterly Activities Report and Appendix 4C
April 23, 2026
Positive SOF-SKN dosing data shows prolonged skin retention
April 21, 2026
Noxopharm appoints Dr Olivier Laczka as new CEO
April 14, 2026
Resignation of Chief Executive Officer
April 14, 2026
Appendix 4D and FY2026 Half Year Financial Report
February 27, 2026
R&D rebate strengthens cash position
February 26, 2026
At-the-Market (ATM) agreement with Acuity Capital
February 26, 2026
Sofra breakthrough science publish in major medical journal
February 10, 2026
December 2025 Quarterly Activities Report and Appendix 4C
January 29, 2026
HERACLES clinical trial successfully completed
January 20, 2026
HERACLES clinical trial Update 5
December 2, 2025
First dose in HERACLES clinical trial Part Two
November 16, 2025
Second part of HERACLES clinical trial begins
November 4, 2025
September 2025 Quarterly Activities Report and Appendix 4C
October 29, 2025
First US patent for Sofra technology platform
October 21, 2025
Extension of Convertible Notes and Funding
September 22, 2025
HERACLES clinical trial Update 4
September 7, 2025
Appendix 4E Preliminary Final Report
August 28, 2025
HERACLES clinical trial Update 3
August 24, 2025
HERACLES clinical trial Update 2
August 10, 2025
US company demonstrates strong Sofra potential
August 4, 2025
June 2025 Quarterly Activities Report and Appendix 4C
July 29, 2025
HERACLES clinical trial - Update 1
July 28, 2025
First SOF-SKN dose in HERACLES clinical trial
July 15, 2025
Promising Sofra results from overseas company
June 11, 2025
Green light for HERACLES clinical trial
May 28, 2025
New funds from Nyrada share sales
May 19, 2025
March 2025 Quarterly Activities Report and Appendix 4C
April 29, 2025
Appendix 4D and FY2025 Half Year Financial Report
February 25, 2025
SOF-SKN passes required in vitro safety tests
February 3, 2025
December 2024 Quarterly Activities Report and Appendix 4C
January 28, 2025
Additional convertible note for long-term shareholder
November 4, 2024
September 2024 Quarterly Activities report and Appendix 4C
October 28, 2024
New funding from sophisticated investors
September 27, 2024
Advanced funding secured ahead of R&D rebate
September 5, 2024
Significant results from new brain cancer drugs
September 2, 2024
Noxopharm Targets Clinical Trial for First-in-Class Drug
August 19, 2024
Significant CRO-67 Results in Pancreatic Cancer Studies
August 14, 2024
June 2024 Quarterly Activities Report and Appendix 4C
July 22, 2024
March 2024 Quarterly Activities Report and Appendix 4C
April 28, 2024